Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Talineuren (InnoMedica, 9b4333)
- Development stage
- Unknown
- Lead developer
- InnoMedica
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Talineuren (TLN-1) is a liposomal formulation of the monosialotetrahexosylganglioside (GM1) ganglioside, developed by InnoMedica Holding AG. GM1 is a naturally occurring glycosphingolipid in the outer leaflet of neuronal membranes, known for its neuroprotective and neurorestorative properties. However, its therapeutic use has been limited by poor blood-brain barrier (BBB) penetration. Talineuren utilizes a specialized liposomal nanocarrier—composed of cholesterol and sphingomyelin—designed to enhance the bioavailability of GM1 and facilitate its transport across the BBB to reach vulnerable neuronal populations. It is primarily being investigated for the treatment of neurodegenerative disorders, including Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS).
- Brand names
- Talineuren
- Other names
- monosialotetrahexosylganglioside liposomalliposomal GM1
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on Talineuren (InnoMedica, 9b4333).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Talineuren (InnoMedica, 9b4333).